Stock events for Foghorn Therapeutics, Inc. (FHTX)
In the past six months, Foghorn Therapeutics provided its first and second-quarter 2025 financial and corporate updates, and announced its participation in investor conferences. The company announced progress for its Selective ARID1B degrader program and scheduled a virtual investor event to review pipeline updates for its degrader programs. The stock gained more than 5% in after-hours trading on October 24, 2025. The company reported a net loss of $86.6 million for the year ended December 31, 2024, and revenue from its collaboration with Lilly was $22.6 million.
Demand Seasonality affecting Foghorn Therapeutics, Inc.’s stock price
For Foghorn Therapeutics, demand seasonality refers to the historical performance patterns of its stock rather than product demand. Historically, buying FHTX stock in June has shown the highest probability of a positive return, while January has exhibited the lowest probability.
Overview of Foghorn Therapeutics, Inc.’s business
Foghorn Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing precision medicines by targeting genetically determined dependencies within the chromatin regulatory system to treat serious diseases through correcting abnormal gene expression. The company operates in the Healthcare sector and Biotechnology industry, utilizing its Gene Traffic Control platform to identify and target drug candidates. Its oncology product candidates include FHD-286 and FHD-609, aimed at treating hematologic cancers and solid tumors, and it is advancing programs for selective ARID1B, CBP, and EP300 degraders. Foghorn Therapeutics also has a collaboration agreement with Eli Lilly and Company for the development of FHD-909.
FHTX’s Geographic footprint
Foghorn Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States, with primary operations focused on research and development.
FHTX Corporate Image Assessment
In the past year, Foghorn Therapeutics' reputation has been shaped by its ongoing progress in clinical development and corporate activities, including advancements in its oncology programs, board appointments, and the annual general meeting. There is no readily available information suggesting any specific events that have negatively impacted Foghorn Therapeutics' brand reputation.
Ownership
Institutions hold a significant portion of Foghorn Therapeutics Inc.'s stock, and it also has a fair amount of insider ownership.
Ask Our Expert AI Analyst
Price Chart
$4.41
